

## Collaborative Biobank Synopsis

<b>Coordinating Investigator</b>	Prof. Dr. med. Johannes Schetelig, M.Sc.
<b>Project Design</b>	<p>The Collaborative Biobank is set up as cooperation project between DKMS gGmbH (DKMS), Transplantation- und Collection Centres in Germany.</p> <p>Primary goal of the biobank is to provide a fundamental basement for future research to optimize the cure of blood cancer diseases in general. Cooperating partners collect samples and linked medical data of patients and stem cells donors that gave written consent to participate in the Collaborative Biobank.</p> <p>In addition, the Collaborative Biobank enables the possibility for Transplantation Centres to use the database also for local centre-specific documentation.</p> <p>Due to the defined ownership of sample material received from Transplantation and Collection Centres, DKMS intends to use those designated samples mainly to improve donor selection. The transfer of ownership of donated sample and the use of data will be contractually agreed on. All participating Transplantation Centres have the possibility to use samples and data additionally for research projects regarding the prevention, diagnosis and treatment of blood cancer.</p> <p>The Collaborative Biobank will be coordinated and administered by the Clinical Trials Unit (CTU) of DKMS. All laboratory processes will be executed by the contracted Sample Administrator. The administration of personal identifying data as well as mapping to pseudonymized data within the Collaborative Biobank will be secured by an external Trusted Third Party.</p>
<b>Primary Endpoint</b>	Establishment of resources for research projects intended to improve prevention, diagnosis and treatment of blood cancer, especially regarding allogenic blood stem cell transplantations.

<b>Secondary Endpoints</b>	<ol style="list-style-type: none"> <li>1. To serve as a resource for research projects intended to improve prevention, diagnosis and treatment of blood cancer.</li> <li>2. To conduct research aiming to improve the outcome of HSCT.</li> <li>3. To improve donor selection for allogeneic stem cell transplantation. In this context the Biobank is intended to be used to optimize the typing panel by using modern sequencing techniques and improving donor selection algorithms.</li> </ol>
<b>Selection of participants</b>	<p>Inclusion criteria:</p> <ol style="list-style-type: none"> <li>1. Patients and donors aged capable of making decisions <math>\geq 18</math> years.</li> <li>2. Voluntary participation.</li> <li>3. Signed Informed Consent.</li> </ol>
<b>Material &amp; Methods</b>	<p>A maximum of 20 ml blood will be collected in EDTA tubes and stored. DNA shall be isolated at a different time point. All laboratory processes are conducted in accordance to Standard Operating Procedures (SOPs). Samples will be stored at -20°C and -80°C.</p>
<b>Recruitment</b>	<p>No limit.</p>
<b>Timeframe and Duration</b>	<p>The Collaborative Biobank has no defined endpoint for recruitment and storage of samples. Samples will be stored for 25 years.</p>
<b>Restrictions/Termination</b>	<p>Temporary or permanent restrictions for recruitment could occur related to the capacity to store samples, financial restraints, or if contracted partners terminate a service on which the Biobank relies. Consequences of termination and resulting legal claims of contracted partners are regulated in the specific Cooperation Contract and Data Protection Agreement of each participating Centre.</p>